To conduct the study, Mao teamed up with Dr. Wenjun Zhong, an epidemiologist at Merck Research Laboratories in West Point, Pa. To analyze the association of more than 50 common risk factors such as smoking, alcohol use, exercise, metabolic risk. Factors, medication use and family history of cancer incidence in 1,303 type 1 diabetes patients with data collected over 28 years.
They collected data from the Diabetes Control and Complications Trial (DCCT) and its follow-up, the Epidemiology of Diabetes Interventions and Complications (EDIC) study, from the National Institutes of Health and Human Services. central database on diabetes and gastrointestinal and kidney diseases and perform statistical analysis on them. The DCCT was a controlled clinical trial involving 1,441 patients with type 1 diabetes who were randomized to conventional or intensive therapy to assess whether the reduction of hyperglycemia blood sugar reduces the risk of complications of type 1 diabetes.
Mao also found that age and sex were associated with cancer incidence when assessed separately, and that daily insulin doses were associated with a higher cancer risk with age, especially higher insulin doses.
Advertisement
According to the article, when the daily insulin dose was classified into three groups, low: less than 0.5; average: greater than or equal to 0.5 or less than 0.8; and high: greater than or equal to 0.8 units/kg per day, the risk ratio was significantly higher in the high-dose group than in the low-dose group. Cancer incidence rates were 2.11, 2.87 and 2.91 per 1,000 people in the low, medium and high insulin dose groups, respectively.
He went on to explain that women are at higher risk than men; however, it remains unclear what risk factors may contribute to the increased incidence of cancer in type 1 diabetes.
Liz Beverly, Ph.D. co-director of the diabetes institute and professor at Heritage College, said. “Dr. Mao’s research identifies a potential mechanism to explain this association. His findings will lead to further research in this area and potential policy changes in cancer screening. letter and insulin dosing recommendations.”
Although previous studies have concluded that diabetics have a higher overall risk of cancer, this is the first study to explore the cancer-related incidence factors in diabetes. Type 1.
“Type 1 diabetes is estimated to account for about 5 to 10% of all diabetes cases, and recent studies of type 1 diabetes also show an increased incidence of certain cancers such as stomach, liver, prostate, and prostate. Pancreatic, endometrial, and kidney cancers are higher in the general population than in the general population,” explains Mao. “Meanwhile, in type 2 diabetes, the increased risk is due to metabolic factors. such as obesity, chronic inflammation and insulin resistance.”
Although the study results showed that the higher the insulin dose, the higher the cancer incidence, Mao said that further investigation was still needed.
Mao graduated from Peking University with a Ph.D. and Ph.D. from Peking University. and did residency training in internal medicine at Cleveland Akron General Clinic and peer training in Endocrinology, Diabetes, and Metabolism at the University of Arkansas. Since then, he has worked at Ohio University as an assistant clinical professor in the Department of Specialty Medicine and the Institute of Diabetes. He is also working with OhioHealth as an endocrinologist at the Castrop Center and at O’Bleness Hospital. His expertise is in diabetes, thyroid diseases, osteoporosis and other endocrine disorders. In addition to the current research, he is also conducting several other clinical trials on obesity, type 1 diabetes and type 2 diabetes.
Source: Eurekalert
